DUBLIN–(BUSINESS WIRE)–The “mRNA Therapeutics and mRNA Vaccines Market by Route of Administration, Therapeutic Area, and Geography: Global Trends and Industry Analysis, 2022-2035” report has been added to ResearchAndMarkets.com’s offering.
Messenger ribonucleic acid (mRNA) is a type of single-stranded ribonucleic acid (RNA), which helps in transferring genetic information in order to produce proteins. The mRNA encoding instructions for protein synthesis are transferred from a strand of DNA to the ribosomes, where these instructions are translated and processed into functional proteins.
Q1. How is the research and development (R&D) activity evolving in the mRNA-based drugs industry?
mRNA therapeutics and mRNA vaccines have emerged as a promising alternative to conventional treatment approaches. Post the onset of the COVID-19 pandemic, mRNA therapeutics and mRNA vaccines have garnered significant attention as they have evolved as a revolutionary novel drug class for the treatment of COVID-19, as well as several other diseases, such as infectious diseases, oncological disorders, genetic disorders and other disorders. Subsequently, upon the approval of the first mRNA vaccine under emergency use authorization (EUA), Comirnaty, in 2020, the field has witnessed a further surge in activity.
Q2. What are the key advantages offered by mRNA therapeutics and mRNA vaccines?
The ongoing research and development efforts being undertaken in this domain are primarily being driven by the various advantages offered by these molecules, including higher biological efficacy, enhanced potent immunogenicity and versatile delivery platforms at reduced toxicity levels, over other therapeutic modalities.
Recent reports highlight the potential benefits related to the use of mRNA; for instance, such products pose no undesirable risk of inadvertent infection and insertional mutagenesis.
Q3. What are the current opportunities in the mRNA vaccines and mRNA therapeutics market?
In the past few years, the field of mRNA therapeutics and mRNA vaccines has evolved at a steady pace. In fact, a significant amount of preclinical data has been gathered and multiple human clinical trials have been initiated. Further, over the past decade, major technological innovations and substantial investments have enabled mRNA to become a promising therapeutic tool in the field of vaccine development and protein replacement therapy. With the advent of several mRNA-based technologies, there has been a rise in the development of these therapeutics to target a myriad of disease indications.
Q4. What are the recent developments and expected trends in the mRNA vaccines and mRNA therapeutics market?
Presently, over 35 companies are engaged in the evaluation of more than 195 mRNA therapeutics and mRNA vaccines, across various stages of development, for a myriad of disease indications. Further, over the coming decade, several promising leads, specifically those exhibiting enhanced efficacy, are anticipated to be commercially launched. Moreover, considering the active involvement of big pharma players, as well as new entrants, the development pipeline of mRNA drugs is likely to grow further.
Q5. What are the key challenges faced by mRNA drug developers?
Despite the numerous benefits offered by mRNA therapies, developers of these novel products often face challenges related to the stability and targeted delivery of their drug candidates. Some of the other key concerns faced by drug developers include limited availability of expertise, lack of specialized infrastructure, requirement for exorbitant capital investment, and constraints associated with ensuring compliance to good manufacturing practices (GMP).
Q6. What are the key value drivers in the mRNA vaccines and mRNA therapeutics market?
The key value drivers in the mRNA therapeutics and mRNA vaccines market include a significant rise in the overall healthcare expenditure, increased R&D spending, a surge in mRNA-focused research initiatives and a plethora of mRNA technological advancements in the recent past.
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET OVERVIEW
5. COMPETITIVE LANDSCAPE
6. COMPANY COMPETITIVENESS ANALYSIS
7. DRUG PROFILES
8. BIG PHARMA INITIATIVES
9. START-UP HEALTH INDEXING
10. CLINICAL TRIAL ANALYSIS
11. PARTNERSHIPS AND COLLABORATIONS
12. FUNDING AND INVESTMENT ANALYSIS
13. PATENT ANALYSIS
14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
15. CONCLUSION
16. INTERVIEW AND SURVEY TRANSCRIPTS
17. APPENDIX I: TABULATED DATA
18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Companies Mentioned
8VC
Abu Dhabi Investment Authority
ACM Biolabs
Acuitas Therapeutics
Adium Pharma
African Union
AIM Vaccine
Albany Molecular Research
Alcobra
Aldevron
Alexandria Venture Investments
Alexion Pharmaceuticals
Amazon Web Services
Amgen
Arcturus Therapeutics
ArrowMark Partners
Astellas
Astellas Innovation Management (Subsidiary of Astellas Pharma)
AstraZeneca
Atlas Venture
Avidity Partners
Axcelead
Baden-Wurttemberg Supply Institution for Doctors, Dentists and Veterinarians
Baidu
Baillie Gifford
Baird Capital
Baupost
Bavarian State Ministry for Economic Affairs, Regional Development and Energy
Baxter BioPharma Solutions
Bayer
BB Biotech
BeiGene
Bill & Melinda Gates Foundation
Biomedical Advanced Research and Development Authority
BioNTech
BIORCHESTRA
Biovac
Black Forest SICAV-SIF
BlueIO
Boehringer Ingelheim
Boehringer Ingelheim Venture Fund
BofA Securities
Boston Biotech Ventures
Brookside Capital
BVCF Management
BVF Partners
Cancer Research Institute
CanSino Biologics
Carlos III National Center for Cardiovascular Research (CNIC)
Catalent
CDH Investments
Central Innovation Programme for SMEs (ZIM)
Changhai Hospital
Charles River
Chartwave
Chiesi Farmaceutici
Chimeron Bio
China Growth Capital
China Merchants Medical and Health Industry Equity Fund
cmRNAbone consortium
Coalition for Epidemic Preparedness Innovations (CEPI)
Codex DNA
Colt Ventures
ConserV Bioscience
Continental Grain Company
Coppel family
Cormorant Asset Management
Co-win Ventures
CPE Yuanfeng
And More
For more information about this report visit https://www.researchandmarkets.com/r/3dlhdv
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
